Aribio, AR1001 Phase 3 Global Clinical Trial Progress Over 80%... "Interim Results by Mid-Year"

Aribio, which is in the process of merging with Solux, announced on the 13th that patient recruitment for the global Phase 3 clinical trial of AR1001 has exceeded 80%. In particular, the recruitment goal was achieved early in the United States, which accounts for the largest portion of the global trial, completing patient enrollment.

Clinical trials in the UK, Europe, Korea, and China will proceed after the US. The company plans to complete patient recruitment within three months, and the lower-than-expected dropout rate is also helping to achieve the early target.

The company stated, "As the interim results are scheduled to be announced mid-year, there is significant interest in the progress and speed of AR1001’s Phase 3 clinical trial," adding, "We expect negotiations for technology transfer of global rights to accelerate following the interim results announcement."

Aribio’s AR1001 is a new oral drug under development for the treatment of Alzheimer's disease. Currently, after completing Phase 2, the Phase 3 clinical trial is underway involving 1,150 patients across 13 countries globally. Earlier this year, AR1001 received higher scores than Leqembi in clinical evaluations of efficacy, safety, dosing convenience, dosing frequency, and known data, according to the UK-based GlobalData report, a renowned medical data information source. Last month, AR1001 also attracted significant attention at the JP Morgan Healthcare Conference (JPM) held in San Francisco, USA.

James Rock, who is in charge of clinical operations at Aribio’s US branch, said, “The global Phase 3 clinical trial is seeing more active participation from patients and their families than any previous trials we have conducted,” adding, “Despite the recent approval of new Alzheimer’s treatments such as Leqembi and Kisunla, the recruitment speed for this trial is exceeding expectations due to the novel mechanism and dosing convenience.”

Meanwhile, at JPM, the company held business meetings with global major pharmaceutical companies, receiving about 30 expressions of interest related to exclusive licensing agreements and investment attraction for AR1001. Among these, five letters of intent (LOI) were received, leading to term sheet discussions for investment, and two term sheets were signed on-site.

This content was produced with the assistance of AI translation services.